“…The evolutionary development of this 5-HT 3 receptor antagonist class has generated many structural analogs designed to improve selectivity, reduce side effects, and improve ligand pharmacodynamics for delayed emesis compared to acute emesis, bringing additional ‘setron’ ligands, such as granisetron, ramosetron, dolasetron, tropisetron, and the second-generation ligand, palonosetron. These advances have been thoroughly reviewed [ 8 , 19 , 21 , 22 , 151 , 217 , 218 , 219 ]. This drug class possesses excellent antiemetic treatment and prophylaxis effects due to their ability to inhibit serotonin activity on both the central nervous system in the chemoreceptor trigger zone and peripherally on gastrointestinal vagal nerve terminals [ 22 , 30 , 217 , 218 , 220 ].…”